Inspire Medical Systems, Inc. develops and commercializes minimally invasive solutions for obstructive sleep apnea (OSA). Its primary product, the Inspire system, utilizes neurostimulation technology to treat moderate to severe OSA. Revenue primarily comes from the sale of the Inspire system and related services, with approximately 70-80% of revenue derived from the Inspire system and the remainder from ongoing patient monitoring and support services. Factors supporting the company's endurance include the growing prevalence of OSA and the increasing acceptance of innovative treatment options. However, potential limitations include competition from other OSA treatments and regulatory challenges in medical device approval.
—
Inspire Medical Systems, Inc. develops and commercializes minimally invasive solutions for obstructive sleep apnea (OSA). Its primary product, the Inspire system, utilizes neurostimulation technology to treat moderate to severe OSA. Revenue primarily comes from the sale of the Inspire system and related services, with approximately 70-80% of revenue derived from the Inspire system and the remainder from ongoing patient monitoring and support services. Factors supporting the company's endurance include the growing prevalence of OSA and the increasing acceptance of innovative treatment options. However, potential limitations include competition from other OSA treatments and regulatory challenges in medical device approval.
—
Daily adjusted close
Inspire Medical Systems, Inc. develops and commercializes minimally invasive solutions for obstructive sleep apnea (OSA). Its primary product, the Inspire system, utilizes neurostimulation technology to treat moderate to severe OSA. Revenue primarily comes from the sale of the Inspire system and related services, with approximately 70-80% of revenue derived from the Inspire system and the remainder from ongoing patient monitoring and support services. Factors supporting the company's endurance include the growing prevalence of OSA and the increasing acceptance of innovative treatment options. However, potential limitations include competition from other OSA treatments and regulatory challenges in medical device approval.